CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10184|
|Tumour Type||Lymphoma & Leukemia|
|Indication||Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar|
|Funding Request||Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia|
|Review Status||File-Closed Not Submitted|
|Pre Noc Submission||No|
|NOC Date||April 4, 2019|
|Manufacturer||Teva Canada Innovation|
|Sponsor||Teva Canada Innovation|
|Submission Date (Target Date)||May 22, 2019|
|Submission Deemed Complete|
|Submission Type||Biosimilar – New Drug|
|Stakeholder Input Deadline (target date based on target submission date) ‡||June 5, 2019|
|Final Biosimilar Summary Dossier Issued (target date)|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.